1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Alpha 1 Antitrypsin Deficiency Treatment Market  - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Alpha 1 Antitrypsin Deficiency Treatment Industry: Forecasts to 2025

  • August 2017
  • 153 pages
  • ID: 5091972
In this report:
According to the Forum of International Respiratory Societies (FIRS), COPD affects more than ## million people and is likely to be the fourth leading cause of death in the world by 2030, while asthma affects about ## million people globally.
The North America dominated the global AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025.

Summary

Table of Contents

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Summary

Alpha-1 Antitrypsin also referred as AAT, is a type of protein belongs to the class protease inhibitor. This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body. The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream. The presence of AAT deficiency can be diagnosed using blood test, genetic tests and biopsy tests. Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases, and emphysema diseases. The diagnosis rate for alpha-1 antitrypsin deficiency across the world is one of the crucial indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease can be treated using distinct therapeutic methods including augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Trends and Opportunities

The worldwide increase in the incidences and prevalence of respiratory diseases is estimated to be top driving factor for the overall AAT deficiency market during forecast period. According to the Forum of International Respiratory Societies, COPD affects more than 200 million people and is likely to be the fourth leading cause of death in the globe by 2030, while asthma affects about 235 million people globally. AAT deficiency is most commonly observed in the North America and European countries which is likely to drive the industry. The growing awareness about AAT deficiency disorder in developed countries, technological development in in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for rising blood and plasma derived products would boost the growth of overall AAT deficiency treatment market. The AAT deficiency is frequent, but under diagnosed condition in most of countries. The slow diagnosis rates of AAT deficiency and high cost of treatment is likely to hamper growth of overall AAT deficiency treatment market over forecast period. Alpha-1 antitrypsin deficiency (A1AD) mostly occurs in the Caucasian population of European descent, affecting approximately 100,000 Americans. Nevertheless, most cases of A1AD are undetected, making alpha-1 antitrypsin deficiency a highly under-diagnosed disorder. Also the treatment of AAT deficiency may lead to development of different chronic side effects including back/joint pain, chest pain, musculoskeletal pain, rhinorrhea, sinusitis, fever, nausea, or shortness of breath, peripheral edema, and urticarial. These side effects can sometimes force a patient to discontinue the therapy as alpha-1 antitrypsin is a natural enzyme inhibitor product.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Geographical Segmentation

Geographically, the overall AAT deficiency treatment market has been split into five regions: North America continent, EU, Latin America area, Asia Pacific (APAC), and Middle East (ME) & African continent. The North America dominated the overall AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025. Europe (EU) is forecasted to expand at more important Compound annual growth rate during forecast period and is likely to gain its market share by the end of 2025. All the areas have been farther divided by countries, product class, by material and End-user segments. The competition matrix section included in the analysis is likely to assist the existing players to increase their market shares and additional companies to establish their presence in the overall AAT deficiency treatment market. The study also describes main actors in the segment based on several features such as corporate overview and financial analysis, SWOT study, main business strategies, product portfolio, and recent evolutions. Main companies competing in the non-vascular stents market, and profiled in the market research contain Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by area

North America (NA)

Europe (EU)

Asia-Pac

Latin America

African region & Middle East

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors - A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

TNF Inhibitors: An insightThe TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global ...

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

Stem cell therapy for diabetes and related conditions: An insightThe stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in ...

Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Plasma Protease C1-inhibitor Treatment Industry: Forecasts to 2025

  • $ 5795
  • Industry report
  • October 2017
  • by Transparency Market Research

Global Plasma Protease C1-inhibitor Treatment Market: OverviewThis report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large numbe ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.